In this study from Johns Hopkins, it was found that women with ovarian cancer had better outcomes after the implementation of the Affordable Care Act.
The MONALEESA-7 trial tested the combination of ribociclib with endocrine therapy in premenopausal women with advanced HR-positive/HER2-negative breast cancer.
Select patients with advanced gastric or gastroesophageal junction cancer may benefit from initial therapy with pembrolizumab, according to the KEYNOTE-062 trial.
This study tested first-line treatment with cabazitaxel vs hormonal therapy in patients with metastatic castration-resistant prostate cancer with poor prognosis.
This study compared combination therapy with enzalutamide, abiraterone, and prednisone vs enzalutamide alone in men with metastatic castration-resistant prostate cancer.
Researchers tested the androgen receptor inhibitor apalutamide plus ADT in patients with metastatic castration-sensitive prostate cancer.
The researchers compared hormonotherapy plus radiotherapy vs radiotherapy alone in prostate cancer patients who previously underwent radical prostatectomy.
The TOPARP-B study showed that olaparib had activity in patients with metastatic castration-resistant prostate cancer with DNA damage repair gene defects.
A computer modeling analysis studied the use of NGS and its costs in patients with metastatic non–small-cell lung cancer.
A new study identified several T-cell antigens that are shared between tumor tissue and skin in a cohort of patients with non–small-cell lung cancer who were treated with anti–PD-1 therapy.